IDIAZ Stock Overview
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Idorsia Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF1.82 |
| 52 Week High | CHF9.72 |
| 52 Week Low | CHF1.29 |
| Beta | 0.82 |
| 1 Month Change | -23.15% |
| 3 Month Change | 24.86% |
| 1 Year Change | -78.69% |
| 3 Year Change | -92.04% |
| 5 Year Change | -90.95% |
| Change since IPO | -87.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| IDIAZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 3.6% | 3.4% | 1.1% |
| 1Y | -78.7% | -25.7% | 1.9% |
Return vs Industry: IDIAZ underperformed the UK Biotechs industry which returned -25.7% over the past year.
Return vs Market: IDIAZ underperformed the UK Market which returned 2.3% over the past year.
Price Volatility
| IDIAZ volatility | |
|---|---|
| IDIAZ Average Weekly Movement | 22.6% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: IDIAZ's share price has been volatile over the past 3 months.
Volatility Over Time: IDIAZ's weekly volatility has increased from 15% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Jean-Paul Clozel | www.idorsia.com |
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia.
Idorsia Ltd Fundamentals Summary
| IDIAZ fundamental statistics | |
|---|---|
| Market cap | CHF323.71m |
| Earnings (TTM) | -CHF374.06m |
| Revenue (TTM) | CHF184.69m |
1.8x
P/S Ratio-0.9x
P/E RatioIs IDIAZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDIAZ income statement (TTM) | |
|---|---|
| Revenue | CHF184.69m |
| Cost of Revenue | CHF349.11m |
| Gross Profit | -CHF164.42m |
| Other Expenses | CHF209.63m |
| Earnings | -CHF374.06m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 21, 2024
| Earnings per share (EPS) | -2.09 |
| Gross Margin | -89.03% |
| Net Profit Margin | -202.54% |
| Debt/Equity Ratio | -136.1% |
How did IDIAZ perform over the long term?
See historical performance and comparison